Welcome to our dedicated page for Icecure Medical Ltd. news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on Icecure Medical Ltd. stock.
Overview of IceCure Medical Ltd.
IceCure Medical Ltd (ICCM) is a commercial-stage medical device company specializing in liquid nitrogen-based cryoablation systems. The company develops and markets minimally invasive technologies designed to destroy tumors through cryoablation, offering a viable alternative to traditional surgical tumor removal. By harnessing the power of liquid nitrogen, IceCure's systems create large lethal zones within tumors, providing a safe and efficient method for treating a variety of conditions including breast, kidney, bone, and lung cancers. This technology is proving essential in the shift toward less invasive medical treatments, marking significant advancements in the field of oncology.
Core Business and Technology
The primary focus of IceCure is on research, development, and commercialization of cryoablation therapy systems. Their flagship product leverages advanced cryogenic engineering to deliver precise ablation of both benign and malignant tumors. Using state-of-the-art cryoprobes and proprietary liquid nitrogen systems, IceCure offers a minimally invasive alternative that reduces surgical risks, shortens recovery times, and minimizes patient discomfort compared to conventional surgical methods. This robust technological foundation is supported by a significant portfolio of patents and continued innovation, underscoring the company’s commitment to remaining at the forefront of cryosurgical treatments.
Market Position and Industry Significance
Within the medical device market, IceCure occupies a unique niche by focusing exclusively on cryoablation. The company’s solutions are positioned as important tools for solid tumor treatments in multiple clinical settings, including hospitals and office-based procedures. With a strong emphasis on clinical research, IceCure’s technologies have been validated through extensive studies and trials, further enhancing their credibility among medical professionals. The company’s achievements, such as receiving key regulatory approvals and positive evaluations from expert panels, also contribute to its recognized position within the competitive landscape of minimally invasive surgery technologies.
Clinical Evidence and Research
IceCure’s commitment to rigorous clinical validation is evident in its comprehensive body of research. Multiple studies and clinical trials have demonstrated that cryoablation using IceCure’s systems achieves outcomes comparable to standard surgical interventions but with significantly lower rates of complications and shorter recovery periods. The company’s approach has garnered attention at major medical conferences, and independent studies consistently highlight the efficacy and safety of their methodology. This research-based approach not only drives clinical adoption but also reinforces the trustworthiness and expertise of IceCure’s technology in the field of oncologic treatment.
Innovation and Regulatory Milestones
Innovation is a core driver for IceCure, which continually refines its technology and expands its intellectual property portfolio. With multiple patents already granted and more under review, the company remains dedicated to advancing its cryoablation systems to meet an expanding range of clinical needs. Strategic regulatory approvals across key global markets such as the U.S., Europe, China, and others attest to the quality and reliability of its products. These achievements reflect IceCure’s commitment to improving patient outcomes and strengthening its market presence in the competitive field of medical devices.
Application and Patient Benefits
IceCure’s cryoablation systems are distinguished by their ability to provide effective tumor destruction with minimal patient discomfort. The technology not only reduces the pain and risks associated with conventional surgery but also facilitates faster recovery times, allowing patients to resume their normal lives more quickly. By offering an office-based, easy-to-perform procedure, IceCure is expanding access to advanced treatment options and paving the way for broader acceptance of minimally invasive therapies in oncologic care.
Conclusion
IceCure Medical Ltd stands as a notable innovator in the field of cryoablation therapy. With a deep commitment to clinical research, technological innovation, and regulatory excellence, the company provides a compelling alternative to traditional surgery for tumor management. Its focused approach and comprehensive product portfolio underscore its significance in the broader context of minimally invasive medical treatments, cementing its role as a trusted entity among healthcare professionals and stakeholders worldwide.
IceCure Medical (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology for tumor destruction, has announced its plans to release financial and operational results for the six months ended June 30, 2024. The company will issue a press release before the Nasdaq Stock Market opens on Tuesday, August 20, 2024. Additionally, IceCure will host a conference call and webcast at 10:00 a.m. EDT on the same day to discuss the results and other corporate developments.
Investors and interested parties can access the conference call using the following details:
- US: 1-888-407-2553
- Israel/International: +972-3-918-0696
- Live webcast: https://Veidan.activetrail.biz/IcecureQ2-2024
IceCure Medical (Nasdaq: ICCM) announced positive data from a large multi-institutional study on cryoablation of primary breast cancer in patients ineligible for clinical trials. The study, published in the American Journal of Roentgenology, included 112 high-risk patients with a median age of 71. Recurrence-free rates were 94.7%, 87.8%, and 81.8% at 1, 2, and 3 years, respectively. The study used various cryoablation systems, including IceCure's ProSense®, across 7 U.S. institutions. Treatment showed a low frequency of adverse events (6.3% minor, no moderate or major) and high technical success (98.2%). Researchers concluded that cryoablation remains a safe alternative to surgery with good outcomes, especially for poor surgical candidates due to comorbidities.
IceCure Medical (Nasdaq: ICCM) reported key findings from three clinical studies of its ProSense® cryoablation system for breast cancer treatment at the 32nd Annual Meeting of the Japanese Breast Cancer Society. Highlights include:
1. An independent study by Prof. Fukuma showed a 99.74% recurrence-free rate in 389 patients treated over 10 years.
2. Another study by Prof. Kawamoto found 0% local recurrence in a five-year follow-up.
3. Terumo , IceCure's distribution partner, plans to submit an application for regulatory clearance in Japan by Q1 2025.
The demand for minimally invasive breast cancer treatments was a major theme at the conference, with ProSense® gaining traction due to its efficacy, favorable cosmetic results, and potential immune system benefits.
IceCure Medical (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology for tumor destruction, has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company has been granted a 180-day grace period until January 14, 2025, to regain compliance. During this period, ICCM's shares will continue trading on the Nasdaq Capital Market.
To regain compliance, ICCM's closing bid price must be at least $1.00 for a minimum of ten consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day compliance period, provided it meets other listing requirements. IceCure Medical states that maintaining its Nasdaq listing is a priority and will consider available options to cure the deficiency if necessary.
An independent study published in 'Cancers' supports the efficacy and safety of IceCure's ProSense® cryoablation system for treating metastatic and recurrent breast cancer. Conducted by Prof. Thomas J. Vogl at the University Hospital Frankfurt, the study involved 45 patients, including those with metastatic disease and recurrent tumors up to 4 cm in diameter. Key findings include a 100% complete ablation rate, 8.9% recurrence rate, and no observed complications. This research, featuring a higher-risk patient group than IceCure's U.S. ICE3 study, underscores ProSense®'s viability across a broader spectrum of breast cancer diagnoses. CEO Eyal Shamir emphasized the significance of these results for ProSense® users in Europe, where the system is approved for general breast cancer treatment.
IceCure Medical announced that the FDA has granted regulatory clearance for its next-generation XSense™ Cryoablation System with CryoProbes. The system, which uses extreme cold to destroy tissues, is cleared for the same indications as its predecessor, ProSense®. These include applications in general surgery, dermatology, neurology, thoracic surgery, ENT, gynecology, oncology, proctology, and urology. The technology addresses conditions such as fibroadenomas, kidney tissue, liver metastases, tumors, skin lesions, and warts. CEO Eyal Shamir stated that this clearance validates the safety and efficacy of the platform, potentially enabling the system to address unmet medical needs in the U.S.
IceCure Medical, developer of the ProSense® System for minimally-invasive cryoablation of tumors, announced its participation in the Northland Capital Markets Virtual Growth Conference on June 25, 2024. The company has achieved key milestones, including the completion of the ICE3 trial and FDA submission for the ProSense® System. CEO Eyal Shamir highlighted board members' recent stock purchases as a sign of confidence. The conference will feature presentations from CEO Shamir and CFO Ronen Tsimerman on recent developments and future catalysts. Interested investors can request virtual meetings for more insights.
IceCure Medical (Nasdaq: ICCM) shared positive interim results from its ICESECRET kidney cancer trial at the 3rd Annual Israeli Conference on Interventional Radiology. The trial features the ProSense® System, a cryoablation technology that freezes tumors. Findings show ProSense® is effective, with an 89.5% recurrence-free rate. Further data is expected in Q4 2024, averaging a 3-year follow-up. The global kidney cancer treatment market, valued at $6.92 billion in 2024, is projected to reach $8.78 billion by 2029. ProSense® is approved in the U.S., Europe, and other regions for benign and malignant kidney tumors. The system offers a minimally invasive alternative to surgery, reducing hospitalization and minimally impacting renal function and hemoglobin levels. CEO Eyal Shamir highlighted the favorable reception of data by interventional radiologists and the potential benefits for kidney cancer patients.
IceCure Medical announced the FDA will convene a Medical Device Advisory Committee to review the De Novo Marketing Clearance Request for its ProSense® System, with a decision expected by early 2025. This review acknowledges the potential public health benefits of ProSense® as a minimally invasive treatment for early-stage breast cancer, affecting approximately 65,000 women annually in the U.S.
ProSense® offers cryoablation technology as an alternative to surgical tumor removal and is already approved in several countries. The Advisory Panel will meet in Q4 2024 to discuss the ICE3 study results, showing 96.3% of patients were free from local recurrence at a 5-year follow-up, with 100% patient and physician satisfaction.
IceCure's CEO, Eyal Shamir, emphasized the transparency and public involvement in the process, anticipating that increased awareness could support commercial efforts in the U.S. upon potential regulatory approval.
IceCure Medical reported a strong Q1 2024 performance with a 30% sales growth for its ProSense® cryoablation system, driven by increased adoption in the U.S. and other global markets. The company completed the landmark ICE3 trial for breast cancer, reporting positive final data and submitting it to the FDA for marketing authorization. Financial highlights include a gross profit of $269,000 and net loss reduction to $3.6 million. Operating expenses decreased due to prudent cash management. The company also secured a new patent in Japan and submitted an FDA application for its next-generation XSense™ system.
FAQ
What is the current stock price of Icecure Medical Ltd. (ICCM)?
What is the market cap of Icecure Medical Ltd. (ICCM)?
What is the core business of IceCure Medical Ltd?
How does cryoablation technology work?
Which clinical indications are addressed by IceCure’s products?
What sets IceCure’s technology apart from traditional surgical methods?
How does IceCure validate the efficacy of its cryoablation systems?
In what markets are IceCure’s products available?
What role does intellectual property play in IceCure’s strategy?
What benefits do patients experience with IceCure’s cryoablation treatment?
